Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $1 | $3 |
| - Cash | $1 | $0 | $1 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $2 | $1 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 34.1% | 10.6% | 296.8% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 23.1% | 2.9% | -21.7% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -725.2% | -701.1% | -573.7% | -1,751.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -788% | -747.7% | -603.5% | -1,864.8% |
| EPS Diluted | -1.69 | -1.58 | -1.36 | -1.05 |
| % Growth | -7% | -16.2% | -29.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |